Testosterone Science

FDA, Regulation and Guidelines

HHS Requests Testosterone Therapy Label Updates, Citing New Safety Data

Specific Claim Evaluated

The requested label changes rest mainly on TRAVERSE, which found transdermal testosterone noninferior to placebo for major adverse cardiovascular events, at 7.0% versus 7.3%.

Primary Research Supporting or Contradicting the Claim

In TRAVERSE, the primary cardiovascular end point occurred in 7.0% of the testosterone group and 7.3% of the placebo group, meeting noninferiority (Lincoff et al., 2023). The FDA requested label updates in June 2026 (U.S. Food and Drug Administration, 2026b).

Corrected Evidence-Based Interpretation

The report is correct.

Rationale for Grade

The article states that the changes are proposed, reports the trial figures accurately and notes continued recommendations for prostate monitoring.

References

  1. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
    Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events"
  2. U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
    Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.